Acadia Pharmaceuticals (ACAD) Intangibles (2016 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Intangibles of $106.2 million for Q1 2026, down 9.3% year-over-year from $117.1 million in Q1 2025, and down 2.5% quarter-over-quarter from $108.9 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Intangibles (2016 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Intangibles history runs 10 years deep, the most recent figure standing at $106.2 million for Q1 2026.
- In Q1 2026, Intangibles fell 9.3% year-over-year to $106.2 million; the TTM figure through Mar 2026 stood at $106.2 million (down 9.3% YoY), while the FY2025 annual figure was $108.9 million, down 9.09% from the prior year.
- Intangibles for Q1 2026 stood at $106.2 million, down from $108.9 million in the prior quarter.
- The five-year high for Intangibles was $119.8 million in Q4 2024, with the low at $65.5 million in Q4 2023.
- The 4-year median for Intangibles is $107.9 million (2024), against an average of $98.5 million.
- The sharpest annual moves came in 2024 and 2026: Intangibles jumped 82.9% in 2024, then decreased 9.3% in 2026.
- Acadia Pharmaceuticals' Intangibles stood at $65.5 million in 2023, then soared by 82.9% to $119.8 million in 2024, then declined by 9.09% to $108.9 million in 2025, then fell by 2.5% to $106.2 million in 2026.
- Business Quant data shows ACAD's Intangibles at $106.2 million in Q1 2026, $108.9 million in Q4 2025, and $111.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 103.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103.45 Mn |
| Mar 31, 2026 | 106.17 Mn |
| Dec 31, 2025 | 108.89 Mn |
| Sep 30, 2025 | 111.62 Mn |
| Jun 30, 2025 | 114.34 Mn |
| Mar 31, 2025 | 117.06 Mn |
| Dec 31, 2024 | 119.78 Mn |
| Sep 30, 2024 | 105.52 Mn |
| Jun 30, 2024 | 107.86 Mn |
| Mar 31, 2024 | 119.60 Mn |
| Dec 31, 2023 | 65.49 Mn |
| Sep 30, 2023 | 66.86 Mn |
| Jun 30, 2023 | 68.22 Mn |
| Mar 31, 2023 | 69.58 Mn |
| Jun 30, 2021 | 369,000.00 |
| Mar 31, 2021 | 738,000.00 |
| Dec 31, 2020 | 1.11 Mn |
| Sep 30, 2020 | 1.48 Mn |
| Jun 30, 2020 | 1.85 Mn |
| Mar 31, 2020 | 2.22 Mn |